Cumulative sales of Kanarb surpass 10 billion

Published: 2012-01-13 06:58:00
Updated: 2012-01-13 06:58:00
Boryung Pharmaceutical said its new hypertensive drug Kanarb (fimasartan) generated 10 billion won in sales since its launching last March of last year.

Kanarb’s sales will get a momentum if it is to be successfully landed in general hospitals, Boryung officials said.

Kanarb, angiotensin II...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.